Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.0
Trade Value (12mth)
N/A
1 week
28.57%
1 month
28.57%
YTD
-30.77%
1 year
-27.74%
All time high
N/A
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
N/A
Short Sell (% of issue)
N/A
Date | Announcements |
---|---|
24 July 24 |
Felix sales clinical trial and Oxidative Stress devel update
×
Felix sales clinical trial and Oxidative Stress devel update |
19 July 24 |
Animal activity update - oxidative stress measurement system
×
Animal activity update - oxidative stress measurement system |
06 June 24 |
Dr David Ali appointed full-time Chief Executive Officer
×
Dr David Ali appointed full-time Chief Executive Officer |
06 June 24 |
Details of Company Address
×
Details of Company Address |
03 June 24 |
Notification regarding unquoted securities - MEM
×
Notification regarding unquoted securities - MEM |
03 June 24 |
Application for quotation of securities - MEM
×
Application for quotation of securities - MEM |
03 June 24 |
Notification regarding unquoted securities - MEM
×
Notification regarding unquoted securities - MEM |
03 June 24 |
s708 cleansing statement
×
s708 cleansing statement |
30 May 24 |
Industry experts to expedite animal breeding products
×
Industry experts to expedite animal breeding products |
21 May 24 |
Investor Presentation
×
Investor Presentation |
20 May 24 |
Investor webinar invitation
×
Investor webinar invitation |
20 May 24 |
Felix Japanese trial provides sperm preparation benefits
×
Felix Japanese trial provides sperm preparation benefits |
09 May 24 |
2024 Investor Presentation
×
2024 Investor Presentation |
29 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
18 March 24 |
Felix TM System Sales Orders Accelerate in Japan
×
Felix TM System Sales Orders Accelerate in Japan |
18 March 24 |
EGM update and advance of funds
×
EGM update and advance of funds |
14 March 24 |
Director Appointment - Michael Atkins
×
Director Appointment - Michael Atkins |
14 March 24 |
Initial Director's Interest Notice MA
×
Initial Director's Interest Notice MA |
26 February 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
20 February 24 |
s708A cleansing statement
×
s708A cleansing statement |
19 February 24 |
Application for quotation of securities - MEM
×
Application for quotation of securities - MEM |
19 February 24 |
Notification regarding unquoted securities - MEM
×
Notification regarding unquoted securities - MEM |
19 February 24 |
Notification regarding unquoted securities - MEM
×
Notification regarding unquoted securities - MEM |
15 February 24 |
Results of General Meeting
×
Results of General Meeting |
25 January 24 |
AI-Port Update - Spring Field Trial Yields Positive Results
×
AI-Port Update - Spring Field Trial Yields Positive Results |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.